Rice Hall James & Associates LLC lifted its position in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 23.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 683,937 shares of the biopharmaceutical company’s stock after buying an additional […]
Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 14,390,000 shares, a growth of 16.0% from the December 15th total of 12,400,000 shares. Based on an average trading volume of 1,720,000 shares, the short-interest ratio […]
Revance Therapeutics (NASDAQ:RVNC – Free Report) had its target price trimmed by Needham & Company LLC from $25.00 to $20.00 in a research report report published on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. RVNC has been the topic of a number of other reports. StockNews.com started […]
Revance Therapeutics (NASDAQ:RVNC – Free Report) had its target price cut by Needham & Company LLC from $25.00 to $20.00 in a report released on Tuesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. A number of other research firms also recently weighed in on RVNC. Morgan Stanley reduced […]